2. Search Result
Search Result
Results for "

4c

" in MedChemExpress (MCE) Product Catalog:

307

Inhibitors & Agonists

1

Fluorescent Dyes

6

Biochemical Assay Reagents

10

Peptides

8

Inhibitory Antibodies

2

Natural
Products

51

Recombinant Proteins

30

Isotope-Labeled Compounds

49

Antibodies

9

Click Chemistry

67

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1363B
    β-Amyloid (1-42), human, HFIP-treated
    Maximum Cited Publications
    24 Publications Verification

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death [4] .
    β-Amyloid (1-42), human, HFIP-treated
  • HY-126217
    hGPR91 antagonist 1
    3 Publications Verification

    		 Succinate Receptor 1 Metabolic Disease
    hGPR91 antagonist 1 (Compound 4c) is a potent and selective GPR91 antagonist with an IC50 of 7 nM for human GPR91 .
    hGPR91 antagonist 1
  • HY-130653
    Azido-PEG4-C2-acid

    		PROTAC Linkers ADC Linker Inflammation/Immunology Cancer
    Azido-PEG4-C2-acid a PEG-based PROTAC linker can be used in the synthesis of vRucaparib-TP4. Azido-PEG4-C2-acid is also a non-cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG4-C2-acid is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azido-PEG4-C2-acid
  • HY-P3732
    RGD-4C

    		Integrin Cancer
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
    RGD-4C
  • HY-100014
    KDM5A-IN-1
    4 Publications Verification

    		 Histone Demethylase Cancer
    KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .
    KDM5A-IN-1
  • HY-23167
    Acid-PEG4-C2-Boc

    		PROTAC Linkers Cancer
    Acid-PEG4-C2-Boc is a PEG- and Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs for the inhibition of mTOR .
    Acid-PEG4-C2-Boc
  • HY-130396
    DBCO-PEG4-C2-acid

    		PROTAC Linkers Cancer
    DBCO-PEG4-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DBCO-PEG4-C2-acid is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-C2-acid
  • HY-146148
    KDM4C-IN-1
    2 Publications Verification

    		 Histone Demethylase Cancer
    KDM4C-IN-1 (Compound 4d) is a potent KDM4C inhibitor with an IC50 of 8 nM. KDM4C-IN-1 inhibits the growth of HepG2 and A549 cells with IC50s of 0.8 µM and 1.1 µM, respectively .
    KDM4C-IN-1
  • HY-22335
    Amino-PEG4-C2-amine

    		PROTAC Linkers Cancer
    Amino-PEG4-C2-amine is a PEG-based (4 units) PROTAC linker can be used in the synthesis of PROTACs.
    Amino-PEG4-C2-amine
  • HY-100683
    A12B4C3

    		Phosphatase Cancer
    A12B4C3 is a potent human polynucleotide kinase/phosphatase (hPNKP) inhibitor with an IC50 value of 0.06 μM. A12B4C3 has antiproliferative activity against cancer cells. A12B4C3 can also enhance the radiosensitivity of certain cancer cells .
    A12B4C3
  • HY-146808
    Galectin-3 antagonist 1

    		Galectin Cancer
    Galectin-3 antagonist 1 (compound 15) is a potent and selective Galectin-3 (Gal-3) antagonist with Kd value of 5.3 μM. Meanwhile, Galectin-3 antagonist 1 binds to various Galectin with Kd values of 250 μM (Gal-4N), 18 μM (Gal-4C), 450 μM (Gal-8C), respectively .
    Galectin-3 antagonist 1
  • HY-133597
    4-Chlorocatechol

    		Drug Derivative Others
    4-Chlorocatechol is a major degradation product of 4-chloro-2-aminophenol (4C2AP). 4-Chlorocatechol is also a substrate for catechol 1,2-dioxygenases and chlorocatechol dioxygenase .
    4-Chlorocatechol
  • HY-170510
    GB2095

    		Galectin Cancer
    GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1). GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research .
    GB2095
  • HY-P7061A
    ALX 40-4C Trifluoroacetate
    1 Publications Verification

    		 Apelin Receptor (APJ) CXCR Infection Endocrinology
    ALX 40-4C Trifluoroacetate is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
    ALX 40-4C Trifluoroacetate
  • HY-111639
    2’-O,4’-C-Methyleneuridine

    		Nucleoside Antimetabolite/Analog Others
    2’-O,4’-C-Methyleneuridine (Compound 15a) is a bicyclic nucleoside.
    2’-O,4’-C-Methyleneuridine
  • HY-130091
    NHPI-PEG4-C2-NHS ester

    		ADC Linker Cancer
    NHPI-PEG4-C2-NHS ester is an ADC Linker, which can be used to synthesize antibody-drug conjugates (ADCs) .
    NHPI-PEG4-C2-NHS ester
  • HY-161126
    EGFR-IN-98

    		EGFR Cancer
    EGFR-IN-98 (Compound 4c) is a EGFR inhibitor. The IC50 values of L858R/T790M/C797S and Del19/T790M/C797S are 0.277 μM and 0.089 μM, respectively. EGFR-IN 98 can be used in the study of tumors .
    EGFR-IN-98
  • HY-162324
    MX106-4C

    		Survivin Cancer
    MX106-4C is a survivin inhibitor that selectively kills ABCB1-positive colorectal cancer cells. MX106-4C can exert synergistic anticancer effects with Doxorubicin or resensitize drug-resistant ABCB1 cells to Doxorubicin .
    MX106-4C
  • HY-P7061
    ALX 40-4C

    		CXCR Apelin Receptor (APJ) Infection Endocrinology
    ALX 40-4C is a small peptide inhibitor of the chemokine receptor CXCR4, inhibits SDF-1 from binding CXCR4 with a Ki of 1 μM, and suppresses the replication of X4 strains of HIV-1; ALX 40-4C Trifluoroacetate also acts as an antagonist of the APJ receptor, with an IC50 of 2.9 μM.
    ALX 40-4C
  • HY-42619
    Amino-PEG4-C1-Boc

    		PROTAC Linkers Cancer
    Amino-PEG4-C1-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
    Amino-PEG4-C1-Boc
  • HY-176518
    ssPalmE-P4-C2

    		Liposome Ser/Thr Protease Infection Neurological Disease Metabolic Disease
    ssPalmE-P4-C2 is a SS-cleavable and pH-sensitive lipid-like material (ssPalm) with a vitamin E‑scaffold. ssPalmE-P4-C2 improves gene knockdown activity against FVII with an ED50 of 0.5 mg/kg. ssPalmE-P4-C2 can be used to synthesize lipid nanoparticles (LNPs) for delivering siRNA to the hepatocyte. ssPalmE-P4-C2 can be used for the RNA therapies for dyslipidemia, hepatitis B/C infections and transthyretin amyloidosis research .
    ssPalmE-P4-C2
  • HY-108420
    INK4C-IN-2
    1 Publications Verification

    		 CDK Cancer
    INK4C-IN-2 is a p18 INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED50 of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .
    INK4C-IN-2
  • HY-157821
    Galectin-4-IN-3

    		Galectin Others
    Galectin-4-IN-3 (Compound 11) is a Galectin 4C inhibitor, with a Kd of 160 μM .
    Galectin-4-IN-3
  • HY-177385
    Morpholino C phosphoramidite

    		DNA/RNA Synthesis Others
    Morpholino C phosphoramidite (Compound 4c) is a nucleoside building block that can be used for synthesis of morpholino oligonucleotides. Morpholino C phosphoramidite can be used for oligonucleotide therapies research .
    Morpholino C phosphoramidite
  • HY-155580
    MAO A/HSP90-IN-2

    		Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
    MAO A/HSP90-IN-2
  • HY-173495
    FAK-IN-25

    		FAK Apoptosis Cancer
    FAK-IN-25 (4c) is a FAK inhibitor with an IC50 of 50.98 nM. FAK-IN-25 (4c) induces apoptosis and causes cell cycle arrest at G1 phase. FAK-IN-25 (4c) can be used in cancer research .
    FAK-IN-25
  • HY-136923
    BW A4C

    		Lipoxygenase Inflammation/Immunology
    BW A4C is a selective 5-lipoxygenase (5-LO) inhibitor. BW A4C is also an inhibitor of linoleic acid 8R-dioxygenase in Gaeumannomyces graminis, with an IC50 value of 0.2 μM. BW A4C can be used in research on diseases such as asthma .
    BW A4C
  • HY-130315
    Br-PEG4-C2-Boc

    		ADC Linker PROTAC Linkers Cancer
    Br-PEG4-C2-Boc is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    Br-PEG4-C2-Boc
  • HY-130097
    Ald-Ph-amido-PEG4-C2-acid

    		ADC Linker Cancer
    Ald-Ph-amido-PEG4-C2-acid is a noncleavable linker used for the antibody-drug conjugate (ADC).
    Ald-Ph-amido-PEG4-C2-acid
  • HY-138370
    Boc-NH-PEG4-C2-Boc

    		PROTAC Linkers Cancer
    Boc-NH-PEG4-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
    Boc-NH-PEG4-C2-Boc
  • HY-W586344
    Desamino lenalidomide-4-C-COOH

    		Ligands for E3 Ligase Cancer
    Desamino lenalidomide-4-C-COOH is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-4-C-COOH can be linked to a target protein ligand via a linker to form a PROTAC.
    Desamino lenalidomide-4-C-COOH
  • HY-157820
    Galectin-4-IN-2

    		Galectin Others
    Galectin-4-IN-2 (compound 12) is an inhibitor of galectin 4C with a galectin dissociation constant of 1.6 mM .
    Galectin-4-IN-2
  • HY-115945
    Complex III-IN-1

    		Mitochondrial Metabolism Fungal Infection
    Complex III-IN-1 (Compd 4c-2) is a complex III inhibitor. Complex III-IN-1 shows antifungal activity with an EC50 of 18.53 mg/L against sclerotinia sclerotiorum .
    Complex III-IN-1
  • HY-161610
    FGFR4-IN-21

    		FGFR Cancer
    FGFR4-IN-21 (Compd 4c) is a FGFR4 inhibitor with an IC50 of 33 nM. FGFR4-IN-21 can be used for hepatocellular carcinoma research .
    FGFR4-IN-21
  • HY-156412
    DHFR-IN-10

    		Bacterial Infection
    DHFR-IN-10 (compound 4c) is a potent DHFR inhibitor, with an IC50 of 4.21 μM for M. tuberculosis DHFR enzyme. DHFR-IN-10 exhibits potent antituberculosis efficiency .
    DHFR-IN-10
  • HY-147981
    Tubulin polymerization-IN-31

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-31 (Compound 4c) is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. Tubulin polymerization-IN-31 induces cancer cell apoptosis and shows antitumor activity .
    Tubulin polymerization-IN-31
  • HY-145868
    Tubulin polymerization-IN-3

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-3 (compound 4c) is a potent tubulin polymerization inhibitor, with an IC50 of 3.84 µM. Tubulin polymerization-IN-3 can induce apoptosis in colon cancer cells .
    Tubulin polymerization-IN-3
  • HY-158212
    Dyrk1A-IN-8

    		DYRK Neurological Disease
    Dyrk1A-IN-8 (compound 4C) is a potent inhibitor of Dyrk1A , with the IC50 of 209 nM. Dyrk1A-IN-8 plays an important role in neurodegenerative diseases .
    Dyrk1A-IN-8
  • HY-138806
    PAQ

    		Calcium Channel Neurological Disease
    PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells .
    PAQ
  • HY-144760
    EGFR-IN-3

    		EGFR Apoptosis Cancer
    EGFR-IN-3 (Compound 4c) is a potent EGFR inhibitor with an IC50 of 0.32 µM against EGFRwt-TK. EGFR-IN-3 shows cytotoxic activity against cancer cell lines and induces apoptosis .
    EGFR-IN-3
  • HY-163118
    Topoisomerase II inhibitor 17

    		Topoisomerase Apoptosis Cancer
    Topoisomerase II inhibitor 17 (compound 4c) is an inhibitor of thiazolopyrimidine topoisomerase (Topoisomerase) Top II (IC50: 0.23 μM). Topoisomerase II inhibitor 17 can significantly cause cell cycle disruption and apoptosis .
    Topoisomerase II inhibitor 17
  • HY-162466
    ABA receptor agonist 1

    		Proton Pump Others
    ABA receptor agonist 1 (compound 4c) is a receptor agonist for abscisic acid (ABA). ABA receptor agonist 1 can inhibit seed germination and seedling growth of Arabidopsis and rice, stomatal closure and drought resistance of wheat and soybean .
    ABA receptor agonist 1
  • HY-172397
    Mycobacterium Tuberculosis-IN-7

    		Bacterial Infection
    Mycobacterium Tuberculosis-IN-7 (Compound 4c) inhibits M. tuberculosis H37Ra with MIC of 5.34 μg/mL. Mycobacterium Tuberculosis-IN-7 exhibits slight cytotoxicity in cancer cell Vero, A549, and HepG2 (IC50s >50 μM) .
    Mycobacterium Tuberculosis-IN-7
  • HY-155828
    h-NTPDase-IN-4

    		NTPDase Cancer
    h-NTPDase-IN-4 (compound 4c) is a pan-inhibitor of NTPDase with IC50s of 3.58 μM (h-NTPDase1), 10.21 μM (h-NTPDase2), 0.13 μM (h-NTPDase3), 13.57 μM (h- NTPDase8).
    h-NTPDase-IN-4
  • HY-161645
    P-gp modulator-4

    		P-glycoprotein Cancer
    P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC50 of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .
    P-gp modulator-4
  • HY-168513
    ALK-IN-29

    		Anaplastic lymphoma kinase (ALK) CDK FAK Cancer
    ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research .
    ALK-IN-29
  • HY-168163
    CDK12/13 ligand 1

    		CDK Cancer
    ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research .
    CDK12/13 ligand 1
  • HY-162482
    EGFR kinase inhibitor 5

    		EGFR Apoptosis Inflammation/Immunology Cancer
    EGFR kinase inhibitor 5 (Compound 4c) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 18.35 μM. EGFR kinase inhibitor 5 induces apoptosis. EGFR kinase inhibitor 5 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg) .
    EGFR kinase inhibitor 5
  • HY-146467
    Anticancer agent 62

    		Drug Derivative Cancer
    Anticancer agent 62 (compound 4c) is a potent anticancer agent. Anticancer agent 62 shows antiproliferative activity in HepG2, Bel-7402 and MCF-7 cancer cells, with IC50 values of 0.019, 0.060 and 0.016 μM, respectively. Anticancer agent 62 shows effective tumor growth inhibition .
    Anticancer agent 62
  • HY-144797
    Tubulin inhibitor 22

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 22 (compound 4c) is a potent inhibitor of tubulin with anti-angiogenesis and anti-cancer properties. Tubulin inhibitor 22 arrests MGC-803 cell cycle at G2/M phase. Tubulin inhibitor 22 dose-dependently causes Caspase-induced apoptosis of MGC-803 cells through mitochondrial dysfunction .
    Tubulin inhibitor 22

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: